Given the entirety of the results from both the toxicology and xenograft studies, we concluded that, at previously established therapeutic doses18, 19, ELP-VEGF had minimal to no adverse effects on renal function, blood pressure, vital organ function, or tumor size. Here, VEGFA is linked to neoplasm.